

# Completing the Otezla START Form



To help prevent delays in the prescription process of your patients on Otezla® (apremilast), be sure to fill out the **Otezla START Form for Specialty Pharmacy and the HIPAA Authorization to Share Health Information** accurately and completely. This guide will help.



## FOUR CHECKS FOR SUCCESS

- 1**  **Refer to the guide provided**  
We've included detailed tips to help you and your patient complete both forms correctly.
- 2**  **Double-check for common errors**  
We've highlighted the fields that are most commonly overlooked. These errors lead to delays in processing. Double-checking may help your patients get their treatment as prescribed and reduce the burden on your office staff.
- 3**  **Make sure you send everything**  
Here's a complete list of what to fax to the specialty pharmacy. (For a list of enhanced support specialty pharmacies, visit the Resources section of [otezlapro.com](http://otezlapro.com)):
  - ◆ Completed and **signed** Otezla START Form for Specialty Pharmacy
  - ◆ Completed and **signed** HIPAA Authorization to Share Health Information
  - ◆ Copy of **both** sides of patient's insurance and pharmacy benefit card(s)
  - ◆ Any clinical notes helpful in establishing diagnosis. **Or**, if the patient has been taking Otezla, include updated clinical notes about their progress
- 4**  **Remind your patients they should expect a call**  
Make sure your patients know that their specialty pharmacy will call to confirm their contact and insurance information – and that call may come from an unfamiliar number. They need to answer to avoid delays in processing.

Questions? Call Otezla SupportPlus™ at **1-844-4OTEZLA** (1-844-468-3952) 8 AM – 8 PM ET, Monday – Friday.  
**Please see Important Safety Information on last page.**

# Sample Otezla START Form for Specialty Pharmacy

Here are some tips for filling out an Otezla START Form for Specialty Pharmacy. Filling out the Otezla START Form and HIPAA Authorization Form accurately and completely will help avoid delays in processing. Highlighted areas note fields that are commonly overlooked.

**START Form for Specialty Pharmacy**

Step 1. Please complete all fields on this form (to prevent delays in processing).  
 Step 2. Fax this form, along with the signed HIPAA Authorization and copies of both sides of insurance and pharmacy benefit cards, to the specialty pharmacy (SP) of your choice. **FAX #** \_\_\_\_\_ **SP NAME** \_\_\_\_\_  
 For assistance or more information, please visit [otezlapro.com](http://otezlapro.com) or call **1-844-4OTEZLA (1-844-468-3952)**.

**Section 1: Patient Information**

Name (First, MI, Last) \_\_\_\_\_ Date of birth: \_\_\_\_/\_\_\_\_/\_\_\_\_  Male  Female  
 Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_  
 E-mail address \_\_\_\_\_ Last 4 digits of SS # \_\_\_\_\_  
 Home phone \_\_\_\_\_  OK to leave message  Mobile phone \_\_\_\_\_  OK to leave message  
 Preferred contact number:  Home  Mobile Best time to reach me:  Morning  Afternoon  Evening

**Section 2: Insurance Information**

Primary insurance name \_\_\_\_\_ Policy # \_\_\_\_\_ Group # \_\_\_\_\_  
 Insurance phone \_\_\_\_\_ Policyholder name (First, MI, Last) \_\_\_\_\_  
 Patient has no insurance  Patient has secondary insurance Name of specialty pharmacy \_\_\_\_\_  
 Pharmacy Benefit Manager (PBM) \_\_\_\_\_ PBM phone \_\_\_\_\_  
 Rx Member ID \_\_\_\_\_ Rx PCN (if applicable) \_\_\_\_\_  
 Rx Group ID \_\_\_\_\_ Rx BIN (if applicable) \_\_\_\_\_  
 I have read and agree to the attached HIPAA Authorization to Share Health Information.  
 Patient/patient representative signature \_\_\_\_\_ Date (MM/DD/YYYY) \_\_\_\_/\_\_\_\_/\_\_\_\_  
*(If signed by patient representative, please explain authority to act on behalf of the patient.)*

**Section 3: Clinical Information (TO BE COMPLETED BY HEALTHCARE PROVIDER)**

**PRIMARY DIAGNOSIS/ ICD-10-CM Code:**  L40.50 (Arthropathic psoriasis, unspecified)  L40.0 (Psoriasis vulgaris) %BSA Affected \_\_\_\_\_  
 L40.51 (Distal interphalangeal psoriatic arthropathy)  L40.8 (Other psoriasis) %BSA Affected \_\_\_\_\_  
 L40.52 (Psoriatic arthritis mutilans)  L40.9 (Psoriasis, unspecified) %BSA Affected \_\_\_\_\_  
 L40.53 (Psoriatic spondylitis)  
 L40.59 (Other psoriatic arthropathy)

**AFFECTED AREA(S) (For PsO ONLY):**  Hands  Arms  Nails  Trunk  Feet  Legs  Scalp  Groin  Other \_\_\_\_\_

**PREVIOUS/CURRENT TREATMENT:**

Medication	Duration/Reason for D/C	Medication	Duration/Reason for D/C
<input type="checkbox"/> Methotrexate	_____	<input type="checkbox"/> Biologics	_____
<input type="checkbox"/> Cyclosporine	_____	<input type="checkbox"/> Topicals	_____
<input type="checkbox"/> Sulfasalazine	_____	<input type="checkbox"/> Other	_____
<input type="checkbox"/> Acitretin	_____		
<input type="checkbox"/> PUVA or UV	_____		

ADDITIONAL MEDICAL JUSTIFICATION \_\_\_\_\_

**Section 4: Prescription Information (TO BE COMPLETED BY HEALTHCARE PROVIDER)**

**PRESCRIPTION FOR OTEZLA (apremilast) FOR ORAL USE: SELECT ALL THAT APPLY**

Starter Pack (Titration) Rx for Otezla\*  4-WEEK STARTER PACK x28 days 55 tablets 0 refills  OR  PRESCRIBER PROVIDED PATIENT WITH 2-WEEK STARTER PACK SAMPLE x14 days 27 tablets 0 refills Date provided \_\_\_\_/\_\_\_\_/\_\_\_\_

Additional information \_\_\_\_\_  
 \*Titration Starter Pack Rx is only for patients who did not receive a titration sample during their office visit. Specialty Pharmacy will notify the patient via telephone prior to each shipment.

Maintenance Rx — 30 mg of Otezla  x30 days  x90 days  TWICE DAILY (Recommended daily dose)  OR  ONCE DAILY (For patients with severe renal impairment)  
 Refills:  11  Other amount (enter #) \_\_\_\_\_ Special instructions \_\_\_\_\_

Bridge Rx — 30 mg of Otezla\*  TWICE DAILY (Recommended daily dose)  OR  ONCE DAILY (For patients with severe renal impairment)  
 x14 days 28 tablets 12 refills x28 days 28 tablets 6 refills

\*Bridge Rx is at no cost, for eligible commercially insured, on-label diagnosed patients only, and not contingent on purchase requirements of any kind. Bridge Rx is not available to enrollees in Medicare, Medicaid, and other federal and state programs, as well as Massachusetts residents. Intended to support continuation of prescribed therapy if there is a delay in determining whether commercial prescription coverage is available.

**Section 5: Prescriber Information (TO BE COMPLETED BY HEALTHCARE PROVIDER)**

Name (First, Last) \_\_\_\_\_ Facility name \_\_\_\_\_  
 Address \_\_\_\_\_ City \_\_\_\_\_  
 State \_\_\_\_\_ ZIP \_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_\_\_ NPI # \_\_\_\_\_ DEA # \_\_\_\_\_  
 Office contact \_\_\_\_\_ Best time to contact:  Morning  Afternoon

**PRESCRIBER AUTHORIZATION\***  
 By signing this START Form I certify that I have prescribed Otezla (apremilast) based on my professional judgment of medical necessity and that I will supervise the patient's medical treatment. I authorize the release of medical and/or other patient information relating to Otezla therapy to agents, and service providers of Celgene (including but not limited to Covance Specialty Pharmacy and Otezla-dispensing pharmacies) to use and disclose as necessary for fulfillment of the prescription and furnish any information on this form to the insurer of the above-named patient.

Prescriber signature (dispense as written) \_\_\_\_\_ Date \_\_\_\_/\_\_\_\_/\_\_\_\_  
 Supervising physician signature and date (where required) \_\_\_\_\_ Date \_\_\_\_/\_\_\_\_/\_\_\_\_  
 Signature stamps not acceptable. \*If required by applicable law, please attach copies of all prescriptions on official state prescription forms.

**OTEZLA SUPPORTPLUS™ Fax: 1-855-850-2955 | Phone: 1-844-468-3952**

Keep a record of the specialty pharmacy to which each form is submitted. Also include this name in Section 2.

P.O. box addresses are not permitted.

If left unchecked, orders may be delayed when information needs to be verified.

In Section 2: All relevant fields must be completed, including patient/patient representative signature and date. **Also** include copy of insurance and pharmacy benefit cards (both sides).

Be sure to document any previous treatments and reasons for discontinuation.

Additional medical justification can help. Also include/attach all clinical notes.

Either select the option for your patient to receive a 4-week starter pack from their specialty pharmacy **or** indicate the date a 2-week starter pack was provided by your office. Be sure to include date.

Bridge supply is only available for commercially insured patients. Patients living in MA are not eligible.

Must include NPI number.

Signature required. **Don't forget to sign and date!**

# Sample HIPAA Authorization Form

Always make sure that the completed Otezla START Form is accompanied by a signed HIPAA Authorization, like the one below.

## HIPAA Authorization to Share Health Information

Fax this signed Authorization, the completed START Form, and copies of both sides of insurance and pharmacy benefit cards, to the specialty pharmacy (SP) of your choice. **FAX #** \_\_\_\_\_ **SP NAME** \_\_\_\_\_  
For more information, or to get answers to your questions, please visit [otezlapro.com](http://otezlapro.com) or call 1-844-4OTEZLA (1-844-468-3952).



Remember to add your fax number and specialty pharmacy of choice. Otezla is available in all SPs.

By signing this Authorization, I authorize my healthcare providers, my health insurance company, and my pharmacy providers to disclose to Celgene and companies working with Celgene (collectively, "Celgene") health information relating to my medical condition, treatment, and insurance coverage to (1) provide me with Celgene-sponsored treatment support services, including online support, financial assistance services, co-pay assistance, reimbursement services, nurse services, and compliance and persistency services, as well as any information or materials related to such services or Celgene products, including promotional or educational communications, (2) provide me with information about, or ask me about my experience with or thoughts about, products, services, and programs that Celgene offers or sponsors, including treatment support services, and (3) allow Celgene to analyze the usage patterns and the effectiveness of Celgene products, services, and programs and help develop new products, services, and programs, and for other Celgene general business and administrative purposes.

I further authorize my healthcare providers, including my pharmacy providers, to use my health information to communicate with me by mail, e-mail, phone, fax or otherwise, about drugs that are currently being prescribed for me, including to remind me about refills of such drugs and adherence to my prescribed drug therapy. I understand that my healthcare providers, including my pharmacy providers, may receive remuneration from Celgene for disclosing my health information to Celgene, and for using my health information to contact me with communications about Celgene products which have been prescribed to me

and Celgene-sponsored services.

Once my health information has been disclosed to Celgene and/or such other individuals, I understand that federal privacy laws may no longer protect the information. However, I understand that Celgene and other companies authorized to receive my health information pursuant to this Authorization agree to protect my health information by using and disclosing it only for purposes authorized in this Authorization or as required by law or regulations.

I understand that I may refuse to sign this Authorization, but that if I do, Otezla SupportPlus™ may not have full access to my prescription status.

I further understand that my treatment (including with a Celgene product), insurance enrollment, and eligibility for insurance benefits are not conditioned upon my signing this Authorization.

I may cancel this Authorization at any time by mailing a letter to Otezla SupportPlus™ at PO BOX 13185, La Jolla, California 92039 or by sending an e-mail to [otezlaprivacy@celgene.com](mailto:otezlaprivacy@celgene.com). I understand that if I revoke this authorization, it will not have any effect on the use of my information by the parties referenced herein before Celgene received the revocation. I also understand that if I revoke this authorization, it will not affect my ability to receive Otezla. This Authorization expires ten [10] years from the day I sign it as indicated by the date next to my signature unless otherwise earlier canceled as set forth above. I understand that I may receive a copy of this Authorization.

I have read and understand the HIPAA Authorization to Share Health Information and agree to the terms.

Signature of patient or patient representative \_\_\_\_\_

Date \_\_\_\_ / \_\_\_\_ / \_\_\_\_

(If signed by patient representative, please explain authority to act on behalf of the patient) \_\_\_\_\_

Signature required.  
**Don't forget to have patient sign and date!**



# Important Safety Information

## INDICATIONS

Otezla® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

## IMPORTANT SAFETY INFORMATION

### Contraindications

- ◆ Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

### Warnings and Precautions

- ◆ **Depression:** Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
- ◆ **Psoriasis:** Treatment with Otezla is associated with an increase in adverse reactions of depression. During clinical trials, 1.3% (12/920) of patients treated with Otezla reported depression compared to 0.4% (2/506) on placebo; 0.1% (1/1308) of Otezla patients discontinued treatment due to depression compared with none on placebo (0/506). Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
- ◆ **Psoriatic Arthritis:** During clinical trials, 1.0% (10/998) of patients treated with Otezla reported depression or depressed mood compared to 0.8% (4/495) treated with placebo; 0.3% (4/1441) of patients treated with Otezla discontinued treatment due to depression or depressed mood compared with none in placebo treated patients (0/495). Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo treated patients (0/495). Suicidal ideation and behavior were observed in 0.2% (3/1441) of patients on Otezla, compared to none on placebo (0/495). Two patients who received placebo committed suicide compared to none on Otezla
- ◆ **Weight Decrease:** Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
- ◆ **Psoriasis:** Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
- ◆ **Psoriatic Arthritis:** Body weight loss of 5-10% was reported in 10% of patients taking Otezla and in 3.3% of patients taking placebo. Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
- ◆ **Drug Interactions:** Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

### Adverse Reactions

- ◆ **Psoriasis:** Adverse reactions reported in ≥5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)
- ◆ **Psoriatic Arthritis:** Adverse reactions reported in ≥2% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, for up to 16 weeks (after the initial 5-day titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2)

### Use in Specific Populations

- ◆ **Pregnancy and Nursing Mothers:** Otezla is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when Otezla is administered to a nursing woman
- ◆ **Renal Impairment:** Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information

Please [click here](#) for Full Prescribing Information.



Otezla® is a registered trademark of Celgene Corporation.  
© 2017 Celgene Corporation 04/17 USII-APR170112

